Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Income from Continuing Operations (2016 - 2025)

Spero Therapeutics' Income from Continuing Operations history spans 10 years, with the latest figure at 31520000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 301.9% year-over-year to 31520000.0; the TTM value through Dec 2025 reached 8565000.0, up 113.42%, while the annual FY2025 figure was 8565000.0, 113.42% up from the prior year.
  • Income from Continuing Operations reached 31520000.0 in Q4 2025 per SPRO's latest filing, up from 7384000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 52234000.0 in Q4 2023 to a low of 30135000.0 in Q1 2022.
  • Average Income from Continuing Operations over 5 years is 7744550.0, with a median of 13565500.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: tumbled 454.02% in 2024, then soared 301.9% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 27426000.0 in 2021, then surged by 215.6% to 31704000.0 in 2022, then surged by 64.76% to 52234000.0 in 2023, then plummeted by 129.89% to 15612000.0 in 2024, then soared by 301.9% to 31520000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Income from Continuing Operations are 31520000.0 (Q4 2025), 7384000.0 (Q3 2025), and 1704000.0 (Q2 2025).